CD274 and cancer: Immune‐targeted therapies approved for cancer include monoclonal antibodies against immune checkpoints like cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4), PD‐1, and programmed cell death ligand 1 (PD‐L1), which aim to modulate the antitumor T‐cell immune response.